jRCTs031200128招募中不适用
Multicenter randomized trial of vonoprazan and high dose amoxicillin dual therapy versus triple therapy with clarithromycin for Helicobacter pylori
未提供0 个研究点目标入组 120 人开始时间: 2020年11月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, Helicobacter pylori culture, anti-Helicobacter pylori antibody test (blood), rapid urease test (biopsy sample), or histological diagnosis (biopsy sample) are treat with infected. Patients who give a written informed consent.
排除标准
- •Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Patients with infectious mononucleosis. Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. Patients using colchicine with liver dysfunction or renal dysfunction. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by phyusicians.
结局指标
主要结局
-
Eradication rate (PPS)
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Sequential therapy with vonoprazan, amoxicillin 7 days and vonoprazan, metronidazole, and sitafloxacin 7 days versus triple therapy with vonoprazan, amoxicillin, and metronidazole 7days for early age Helicobacter pylori infection: a multicentre, open-label, randomised trialHelicobacter pylori infectionJPRN-UMIN000032109Yokohama City University Hospital190
招募中
不适用
Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori EradicatioH. pylori infectionJPRN-UMIN000022963Hamamatsu University School of Medicine100
已完成
4 期
Efficacy and Safety of Dual Therapy for Helicobacter Pylori EradicationHelicobacter Pylori InfectionNCT05469685Nanjing First Hospital, Nanjing Medical University914
尚未招募
3 期
Efficacy of Vonoprazan, Sitafloxacin and Amoxicillin Regimen for Treatment of Refractory Helicobacter pylori infectioPrevalence of helicobacter pylori is 17-55%. Ten to twenty percents of H.pylori infection were failed to treatment with first line regimen. Refractory H.pylori infection defined as H.pylori infection which failed to treatment with at least 2 regimens. There was not standard regimen for H.pylori infection.Refractory Helicobacter pylori, Helicobacter pylori, Resistant Helicobacter pyloriTCTR20211203002Routine to Research Unit, Siriraj Hospital20
招募中
2 期
VAS third-line eradication studyHelicobacter pylori infectionJPRN-jRCTs031190031Soichiro Sue68